Skip to main content
Caplight Logo









Vergent Bioscience

Vergent Bioscience

Private
Minneapolis, MinnesotaHealthcare & Life Scienceshttps://www.vergentbio.com/

Last Round

Grant

Nov 29, 2022

Total Funding Raised

$32.2M

Company Overview

Vergent Bioscience is a biotechnology company that develops tumor-targeted fluorescent imaging agents to improve the visibility of tumors for surgeons during minimally invasive and robotic-assisted surgery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Imaging, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

fluorescent imaging agentimage-guided surgerysurgical oncologytumor paintrobotic-assisted surgerymolecular imagingminimally invasive surgeryVGT-309near-infrared lightNIRsurgical dyelung cancersolid tumorsclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vergent Bioscience Comparables

Compare Vergent Bioscience with similar companies based on industry and business-model similarity.

Vergent Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Blaze Bioscience, Inc.
93%
On Target Laboratories
89%
Avelas Biosciences
84%

Vergent Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 29, 2022
Series BOct 4, 2022
Series AJun 12, 2018

Key People

Founding team and executive leadership

John Santini

President & CEO

Executive Team

Jeff Yurecko

CFO

Executive Team

Vergent Bioscience Investors

Notable investors and investment history

Vergent Bioscience investors
InvestorRounds
National Cancer InstituteGrant
Orlando Health VenturesSeries B
Windham Capital PartnersSeries B
Spring Mountain CapitalSeries A
Rex Health VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2024

    Grew 27% QoQ from 11 to 14 employees.

  • Oct 4, 2022

    $22M round led by Orlando Health Ventures.

Vergent Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vergent Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vergent Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersMinneapolis, Minnesota
Employee Range13
Year Founded2013
Last FundingNov 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?